Source: International Congress 2014 – Acute pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. L. Lobo Bersitain, J. A. García Fuertes, E. Miranda Serrano, I. Casado Moreno, J. Luque Pinilla, M. Barrón Medrano, M. Monreal, RIETE Group (Vitoria-Gasteiz, Granada, Madrid, Logroño, Spain). Venous thromboembolic disease (VTD) associated with inflammatory bowel disease (IBD): RIETE´s experience. Eur Respir J 2014; 44: Suppl. 58, 2398

Member's Comments

No comment yet.

Related content which might interest you: HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Prognosis factors of recurrent pulmonary thromboembolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Improving the safety of right heart catheterisation in sickle cell disease Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). Source: International Congress 2017 – PAH and CTEPH Year: 2017 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Rivaroxaban for treatment of venous thromboembolism. A real-life perspective in 103 patients Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014